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Oral Presentations S179AML in CR1 from 2001-2008. Sixty-one patients were available for
evaluation. Alongwith demographics we reviewed cytogenetics at di-
agnosis, number of induction chemotherapy cycles required to
achieve CR, pre-HCT consolidation therapy, and comorbidity score
at HCT. Impact of pre-HCT consolidation was analyzed in relation
to overall survival (OS), relapse, and transplant related mortality
(TRM).
Patients were a median of 56 years old (range 24-74) and received
either HLA matched sibling (n5 18), cord blood (n5 42) or unre-
lated donor (n5 1) grafts following cylophosphamide, fludarabine
and low dose total body irradiation along with CSA andmycopheno-
late for GVHD prophylaxis. Transplants were all during CR1 and
performed at a median of 5 (range 1.5–8.6) months from diagnosis.
Twenty-six patients received pre-transplant consolidation and 35
received none: 58% and 40% in each group respectively had high
risk cytogenetics.
Results:Of 61 patients, 43% (n5 26) received pre-HCT consolida-
tion therapy, 19 of whom (73%) received 1 cycle (range 1-3). Expo-
sure to pre-HCT consolidation therapy did not significantly alter 2
year OS or incidence of relapse and did not increase TRM. (Table)
In multivariate analysis only HCT-CI significantly impacted 2
year TRM. Relative risk (RR) of TRM at 2 years for patients
with HCT-CI .2 was 4.74 (95% CI, 0.99 – 22.60, p5 0.05).
Exposure to pre-HCT consolidation therapy was associated with
a trend towards improved 2 year TRM with a RR of 0.21 (95%
CI, 0.03 – 1.28), p5 0.09). In multivariate analysis of relapse risk
at 2 years, exposure to consolidation therapy had no effect on
relapse: RR was 1.5 (95% CI, 0.47 – 4.82, p5 0.50). No other
variables tested in multivariate analysis (high comorbidity score,
higher number of induction cycles to achieve CR, or high risk
cytogenetics) impacted relapse.
Conclusion: Consolidation therapy prior to RIC HCT does not
reduce relapse or augment TRM. RIC HCT is less successful in
patients with high HCT-CI due to excess TRM. For patients
with confirmed CR1, consolidation prior to RIC HCT is not
needed.
Two Year Outcomes: Univariate Analysis
No Pre-HCT Consolidation Pre-HCT Consolidationn5 35 n5 26 P-ValueOS 48% (30-64%, 95% CI) 35% (12-59%, 95% CI) 0.74
Relapse 29% (14-45%, 95% CI) 43% (23-62%, 95% CI) 0.23
TRM 27% (12-43%, 95% CI) 6% (0-19%, 95% CI) 0.05LYMPHOMA/MULTIPLE MYELOMA
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MULTI-TUMOR-ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES FOR
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Tumor immunotherapy using in vitro expanded cytotoxic T lym-
phocytes (CTLs) can effectively treat virus-associated malignancies
such as EBV +ve Hodgkin’s Lymphoma. However, extension to
non virus-associated malignancies has been complicated by the
low frequency of circulating T-cells reactive against tumor-
expressed antigens, which are often anergized or tolerized. To
overcome T-cell anergy we activated T cells in the presence of a po-
tent cytokine cocktail including IL12 (Th1 polarizing), IL7 and
IL15 (pro-survival/-proliferative), and IL-6 (Treg inhibitory). We
optimized the generation of polyclonal, multiTA-reactive CTLs
by combining these cytokines with autologous dendritic cells nu-
cleofected with combinations of DNA tumor antigen (TA)-encod-
ing plasmids or pulsed with multiple TA pepmixes as APCs. The
use of whole antigen increases the range of suitable patient HLA
polymorphisms beyond those matched to single peptides, while tar-geting multiple antigens simultaneously reduces the risk of tumor
immune evasion.
Antigen combinations were chosen based on their tumor expres-
sion profile. To target lymphoma we grouped SSX2, Survivin, and
MAGEA4 and were consistently able to generate multiTAA CTL
directed against these three antigens (n5 6 healthy donors). The
lines were polyclonal comprising CD4+ (mean 57+/-7%) and
CD8+ (mean 40+/-16%) T cells, with reactivity against SSX2, Survi-
vin and MAGEA4 (median 345, 290 and 255 spot forming units
(SFU)/1106 CTL respectively in IFNg ELIspot, n5 6). The
CTLs were cytolytic against autologous SSX2 and Survivin pep-
mix-pulsed targets (mean 53% and 30% specific lysis, E:T 40:1)
and against whole Survivin antigen-expressing fibroblasts (30% spe-
cific lysis, E:T 100:1) with no recognition of non-transduced control
targets (9%) in a standard Cr51 release assay. For leukemia we
targeted WT1, Prame, PR3, and Survivin and generated CTL lines
with reactivity against WT1 (mean 733 SFU), PRAME (mean 555
SFU), PR3 (mean 145 SFU), and Survivin (mean 32 SFU/1106
CTL), n5 2.
Hence it is feasible to generate single tumor specific CTL lines
that target multiple tumor antigens simultaneously thereby reducing
the risk of tumor escape and simplifying clinical application.65
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Autologous stem cell transplantation (ASCT) for multiple mye-
loma (MM) offers a unique setting to explore the role of immuno-
therapy in eradicating malignancy. Our group has developed
a cancer vaccine whereby dendritic cells (DCs) are fused with autol-
ogous tumor cells. We are conducting a clinical trial in which MM
patients undergo ASCT followed by vaccination with 3 doses of
DC/MM fusions (cohort 1). A second cohort receives an additional
vaccine prior to stem cell collection (cohort 2). To date, 26 patients
have been enrolled in cohort 1 and 9 in cohort 2. Adherent mononu-
clear cells were isolated from leukapheresis collections and cultured
with GM-CSF, IL-4 and TNFa to generate DCs. MM cells were
isolated from bone marrow and were identified by expression of
CD38 or CD138. DC and MM cells were co-cultured with PEG
and fusion cells were quantified by determining the percentage of
cells that co-express unique DC and MM antigens. Mean fusion
efficiency was 38%, mean dose generated was 3.6  106 fusion cells.
Fusion cells potently stimulated allogeneic T cell proliferation in
vitro (mean stimulation indexes were 13, 60, and 32 for T cells stim-
ulated by MM cells, DCs, and fusion cells respectively). Adverse
events were mild, and included injection site reactions, pruritis,
myalgias, fever, and tachycardia. ASCTwas associated with suppres-
sion of measures of cellular immunity. Circulating CD4 cells were
depressed post-transplant, and CD4:CD8 ratios remained inverted
for .10 months. Following transplant, T cell response to PHA
and tetanus toxoid were depressed. In contrast, an increase in circu-
lating tumor reactive lymphocytes was noted, as determined by T
cell expression of IFN following ex vivo coculture with autologous
myeloma cell lysate (Mean percentage of tumor reactive CD8 cells
was 1 and 7.7 pre and post-transplant, respectively; mean percentage
of CD4 cells was 0.9 and 3.2). A further amplification of tumor reac-
tive lymphocytes was seen with vaccination (mean percentage of
CD4 and CD8 tumor reactive T cells was 6.4 and 13.4, respectively).
24 patients have completed follow up. 3 patients achieved CR at
1 month following ASCT. An additional 7 patients obtained a CR
following completion of vaccinations, supporting a role for post-
transplant immunotherapy in mediating elimination of disease. In
summary, fusion cell vaccination in conjunction with ASCTwas well
tolerated, induced anti-tumor immunity and induction of post-trans-
plant complete response.
